Viking Raised $575 Million In Stock And Debt In September, Yet Holds A $500 Million Buyback Unused

The obesity-drug developer's 10-Q shows $960.0 million in cash, a $500.0 million repurchase plan and third-quarter R&D of $166.8 million.

Share
Viking Raised $575 Million In Stock And Debt In September, Yet Holds A $500 Million Buyback Unused

Viking Therapeutics, a clinical-stage drug developer focused on obesity and other metabolic disorders, sold 9,035,714 shares at $35.00 each in September and issued $258.8 million of 2.00% convertible notes, its 10-Q filed Thursday shows. Over the same stretch its board has kept a $500.0 million buyback authorization on the books, and no shares have been repurchased this year.

Stock, notes and an idle buyback

The share sale brought in gross proceeds of about $316.25 million, and the notes added about $258.8 million. After fees, net proceeds were about $296.9 million and $250.6 million. The offerings included full exercise of the underwriters' options.

In July the board ended a $250.0 million repurchase plan and authorized up to $500.0 million over up to three years. The 10-Q says nothing was repurchased under either plan in the nine months ended September 30, 2026.

Viking also sold 1,476,600 shares through its at-the-market program, which lets it sell stock at market prices. Up to $449.8 million remains available under it.

What the notes could mean for share count

The notes mature October 15, 2032. Conversion at about $50.75 per share could add roughly 5,098,514 shares, though Viking may pay in cash instead.

Shares outstanding stood at 127,521,229 at September 30, up from 114,793,067 at the end of 2025.

R&D nearly doubles as cash swells

Viking has no revenue. Research and development spending reached $166.8 million in the third quarter, against $89.953 million a year earlier, and the net loss was $183.2 million, or $1.55 per share. For the nine months, R&D was $432.7 million, mostly on the two Phase 3 VANQUISH trials of its lead obesity drug, VK2735.

Liquidity, including restricted cash and short-term investments, reached $960.0 million at September 30, versus $501.9 million three months earlier. Management says that funds operations through at least December 31, 2027, compared with September 30, 2027 in the prior filing. The company also says it will need to raise more capital to finish its ongoing and planned trials.

In October it started the SUNRISE Phase 3 program for an oral version of VK2735.

Ligand wants Viking's contract cross-claims dismissed; Viking's response is due February 11, with a court date February 26, 2027.

Sources

More on Viking Therapeutics

All Viking Therapeutics (VKTX) coverage →